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A prospective quasi-experimental study was undertaken in 218 patients with suspicion of nosocomial infection hospitalized
in a polyvalent ICU where a new electronic device (GERB) has been designed for antibiotic prescriptions. Two GERB-based
applications were developed to provide local resistance maps (LRMs) and preliminary microbiological reports with therapeutic
recommendation (PMRTRs). Both applications used the data in the Laboratory Information System of the Microbiology
Department to report on the optimal empiric therapeutic option, based on the most likely susceptibility profile of the
microorganisms potentially responsible for infection in patients and taking into account the local epidemiology of the hospital
department/unit. LRMs were used for antibiotic prescription in 20.2% of the patients and PMRTRs in 78.2%, and active antibiotics
against the finally identified bacteria were prescribed in 80.0% of the former group and 82.4% of the latter. When neither LMRs nor
PMRTRs were considered for empiric treatment prescription, only around 40% of the antibiotics prescribed were active. Hence,
the percentage appropriateness of the empiric antibiotic treatments was significantly higher when LRM or PMRTR guidelines
were followed rather than other criteria. LRMs and PMRTRs applications are dynamic, highly accessible, and readily interpreted
instruments that contribute to the appropriateness of empiric antibiotic treatments.
1. Introduction
Microorganism resistance to antibiotics changes over
time and varies according to geographic area, hospital,
or even hospital department [1, 2]. Various studies on
severe infections in hospitalized patients, especially
those in intensive care units (ICUs), have associated an
inappropriate initial antibiotic treatment with increases
in bacterial resistance, morbidity-mortality, hospital stay,
and hospital costs [3–12]. Selection of the appropriate
empiric antibiotic treatment requires knowledge of
changes in the etiology of infectious processes and
in antibiotic resistance patterns in each hospital area
[13, 14].
The selection of empiric antibiotic therapy is generally
based on updated clinical practice guidelines or therapeutic
recommendations developed by expert groups from scientific
societies [15–17], whichmust be adapted to the epidemiologic
characteristics of each country or healthcare area [13, 18].
Once microbiological results are confirmed and the sat-
isfactory clinical progression of patients is observed, it is
recommended to deescalate antibiotic therapy when possible
in accordance with the antibiograms of the identified bacteria
[3, 6, 10, 11, 15, 19].
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Hospital antibiograms are commonly used to monitor
local trends in antimicrobial resistance and to prepare
antibiotic policies for guiding targeted empiric therapy [20].
Thus, besides the identification and study of microorganism
susceptibility, the microbiology laboratory has a role in
periodically updating results for designing empiric antibiotic
treatment guidelines adapted to the local microbial epi-
demiology [21, 22]. These guidelines should be based on
the best available clinical evidence and on the resistance
profiles in each healthcare setting [6, 18]. They need to be
constantly updated, taking account of the clinical usefulness
of treatments, the ease of their management, and consensus
agreements among professionals [21]. Guidelines are con-
sidered to be more useful when defined and implemented
by a multidisciplinary team and adequately disseminated
and promoted, followed by evaluation of their acceptance
and implementation [23, 24]. Ideally, these guidelines should
be developed for each hospital department, and there is a
particular need to avoid needless antibiotic administration
for a suspected nosocomial infection in the ICU [25].
The objectives of our study were to design, develop,
and implement a new computer application based on the
local epidemiologic analysis of bacterial susceptibility to
antibiotics and to assess the usefulness to physicians of the
information that it offers for selecting the most appropriate
antibiotic treatment in ICU patients with suspicion of noso-
comial infection.
2. Patients and Methods
This study was conducted over a three-year period in a third-
level 821-bed hospital, Complejo Hospitalario Torrecardenas
(CHT), serving 350,000 inhabitants and eight primary care
districts in the province of Almeria (southeast Spain).
2.1. Study Design. A prospective, quasi-experimental study
was conducted in three stages between January 2008 and
December 2010. During the first sixmonths, a new computer-
assisted program was developed for antibiotic selection.
Between July and October 2008, four information sessions
and two round table discussions were conducted with the
specialized physicians and nursing staff of the ICU and
Departments of Microbiology, Preventive Medicine, and
Pharmacy of the hospital to promote the new program
and train participating physicians in its application. Finally,
between October 2008 and December 2010, the new system
was implemented for antibiotic prescription in the ICU, the
patients in the study were followed up, and the results were
analyzed.
2.2. A Computer-Assisted Program for Antibiotic Selection.
We developed an application, based on Microsoft.NET
Framework with Visual C# and SQL, with Open DataBase
Connectivity (ODBC) to the Laboratory Information System
(LIS) of the Hospital Microbiology Department in order to
provide real-time analysis and updating of data obtained
from microbiological studies. The application, designated
Guı́a Electrónica de Resistencias Bacterianas (GERB), was
installed in a central server. The database is automatically
updated and allows consultation of all antibiograms recorded
in the LIS, extracting data according to different selec-
tion criteria (e.g., date or date interval, patients, samples,
diagnoses, microorganisms isolated, antibiotics tested, and
hospital departments), and creating graphics to facilitate
interpretation and visualization on the computer screens in
the network.
TwoGERB-based computer applications were developed:
local resistance maps (LRMs) and preliminary microbiolog-
ical reports with therapeutic recommendation (PMRTRs).
Both guidelines consider the epidemiology, the evidence-
based best treatment options for the most prevalent bacterial
pathogens, and the local-specific antibacterial pathogen sus-
ceptibility.
2.2.1. Local Resistance Maps (LRMs). These maps graphically
depict the accumulated susceptibility data in the LIS for all
bacteria identified in samples from ICU patients during the
previous year and from the patients who have undergone
antibiograms. The GERB system is used to create three types
of LRM for the empiric treatment of lower respiratory tract
infections, based on antibiograms for bacteria isolated from
samples from the lower respiratory tract; urinary tract infec-
tions, based on antibiograms for bacteria isolated from urine
samples; and bacteremias, based on antibiograms of bacteria
isolated from blood cultures. The antibiotics included in the
LRMs were selected by consensus among the ICU physicians;
their inclusion required a minimum of 30 in vitro assays.
The percentage of bacteria susceptible to each antibiotic was
depicted by using a color code: green: susceptible, yellow:
intermediately susceptible, and red: resistant.
Physicians had ready access to themaps via touch screens
located in the ICUs that were connected to the hospital
intranet and automatically updated every 24 h, incorporating
any new records entered into the GERB system.
2.2.2. Preliminary Microbiological Reports with Therapeutic
Recommendation (PMRTRs). A PMRTR was issued when
the microbiology laboratory reported a sample to be posi-
tive according to the culture results but before a definitive
identification and antibiogram.The requesting ICUphysician
was informed about the microorganism genus or isolated
microorganism or, when not available, the result of Gram
staining and was given therapeutic recommendations. These
named the antibiotics with highest activity against the
microorganisms presumably involved and against the specific
infectious disease of the patient, according to the information
in the GERB, and they included the most favorable pharma-
cokinetics and pharmacodynamics properties according to
the infection focus. This signed report was sent directly to a
dedicated remote printer in the ICU.
2.3. Patients. Inclusion criteria for the patients in the poly-
valent 24-bed ICU were as follows: (i) suspicion of noso-
comial infection, defined as developing ≥48 hrs after ICU
admission, in the lower respiratory tract, urinary tract, or
blood (bacteremia), based on clinical symptoms and results
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of laboratory tests or radiologic exam. The focus was micro-
biologically defined as the lower respiratory tract or urinary
tracts when the corresponding microbiological cultures were
positive, regardless of the presence of bloodstream infection;
bacteremia was defined by the isolation of one or more high-
grade pathogens in a blood culture specimen or the identifi-
cation of a common skin contaminant or skin flora in at least
two separate blood culture specimens from different sites in
the same patient; and (ii) susceptibility to antibiotic treatment.
Exclusion criteria were presence of signs of infection or being
in incubation period at admission, referral from another
hospital department or health center, and age under 14 yrs.
The Acute Physiology and Chronic Health Evaluation
(APACHE) II score [26] was determined for each patient,
considering the worst reading in the first 24 h of ICU stay,
in order to evaluate the severity of illness and calculate the
predicted mortality rate.
2.4. Antibiotic Selection Criteria. Antibiotic prescription was
structured in three levels, with the aim of treating patients in
the shortest time possible with the most appropriate antibi-
otic according to the infection focus and clinical situation.
Thefirst level was the implementation of an empiric antibiotic
treatment in patients with clinical suspicion of infection.
For this purpose, ICU physicians had access via the touch
screen in the unit to the LRMs, which depicted the percentage
activity of different antibiotics against the microorganisms
usually detected in each infectious process, allowing them
the possibility of prescribing the treatment in accordance
with these data (guidelines). In the second action level,
after the putative isolation or identification of one or more
microorganisms in a sample from the patient, the physician
received a PMRTR prepared by the microbiology specialists
(see above). Finally, after identification of the bacteria, the
microbiology laboratory issued a definitive report with the
corresponding antibiogram.
The study was conducted under the following conditions:
(i) the information provided by these GERB applications was
not binding in any case. Physicians were not obliged to use
the LRM and/or PMRTR guidelines and could base their
selection of antibiotic therapy on exclusively clinical criteria
(in accordance with the guidelines of the Hospital Infections
Committee); (ii) the selection of antibiotic treatment was
always adapted to the clinical situation of patients and took
account of any therapeutic limitations, including allergies,
drug interactions, and toxicity, considering renal and hepatic
function, administration routes, dose, dose intervals, and
so forth; (iii) in the LRM and/or PMRTR guidelines, an
antibiotic was recommended when active against ≥75% of all
microorganisms isolated in the same infection focus during
the previous 12 months; (iv) broad-spectrum antibiotics
were used for severe infections (especially in low respiratory
tract infections and bacteremias); (v) after receipt of the
PMRTR, the physician was able to modify or maintain
the initial empiric treatment; and (vi) after receipt of the
definitivemicrobiological report, with bacterial identification
and corresponding antibiogram, deescalation was conducted
when indicated, selecting the most appropriate antibiotic(s)
according to clinical, microbiological, and pharmacological
criteria. No study was made of the reasons for the therapeutic
decisions taken by the physicians in this study.
Antibiotic treatment was considered appropriate when
at least one of the prescribed antibiotics was active in vitro
against the isolated microorganism(s) and the drug regimen
was in accordance with current medical standards. The
appropriateness of the therapeutic option and/or antibiotic
prescription was assessed by comparing each of the antibi-
otics recommended and/or prescribed in a patient with
the definitive antibiogram of the microorganism(s) finally
identified as the causal agent, when available. An antibiotic
with synergic activity, for example, aminoglycosides, was not
considered appropriate when it was the only antibiotic active
against the isolate in vitro.
2.5. Data Collection. Data were gathered in all studied
patients on admission date, sex, age, main diagnosis, per-
sonal history of interest (allergies, other diseases, previous
medication, etc.), chronic organ failure (hepatic, renal, pul-
monary, cardiovascular, and immunosuppression, as defined
by APACHE II), clinical progress during hospital stay using
a semiquantitative scale [27], analytical results (full blood
count, biochemistry, cultures, etc.), and daily body temper-
ature. Other variables recorded were the empiric antibiotic
treatment selected (indicating whether LRM guidelines were
followed or not), any treatment change (indicating whether
PMRTR recommendation was followed), the dose, dosing
frequency, administration route, possible toxicity, total hospi-
tal stay, and date of discharge or death. Patients were followed
up until their death or ICU discharge.
2.6. Statistical Analysis. SPSS 17.0 for Windows was used for
the data analyses. Pearson’s chi-square test (with continuity
correctionwhen required) was used to compare the appropri-
ateness of prescribed antibiotic treatments according to the
application of clinical criteria, LRM guidelines, or PMRTR
recommendations and to compare patient mortality rates
in each of these situations and when no empiric treatment
was administered. Fisher’s exact test in a 2 × 2 tables was
used when the sample size was too small and conditions
for Pearson’s chi-square test application were not met. The
Student’s t-test was employed to compare the mean days
of ICU stay as a function of the criteria used for empiric
antibiotic treatment prescription (clinical, LRM, or PMRTR)
and the receipt or not empiric treatment.TheMann-Whitney
U test was used when the distribution of a variable was
nonnormal according to the results of a previously applied
Shapiro-Wilk test. 𝑃 < 0.05 was considered significant in all
tests.
3. Results
Between October 2008 and December 2010, 218 patients in
the ICU of our hospital met the study eligibility criteria, 139
males (63.8%) and 79 females (36.2%).Themean APACHE II
score of the study cohort was 16.9 ± 7.5 (range, 2–40).
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Table 1: Distribution by sample type of the 262 microorganisms isolated in the 137 patients.
Microorganism Respiratory samples Urine Blood cultures Total
Acinetobacter baumannii 2 1 3 6
Bacteroides fragilis 3 3
Candida albicans 4 5 9
Candida parapsilosis 1 1 2
Candida tropicalis 2 2
Citrobacter koseri 5 1 6
Enterobacter aerogenes 4 1 5
Enterobacter cloacae 10 10
Enterobacter sakazakii 1 1
Enterococcus faecalis 2 7 9
Enterococcus faecium 1 1 2
Escherichia coli 22 7 2 31
Haemophilus influenza 8 8
Klebsiella oxytoca 4 4
Klebsiella pneumoniae 18 3 21
Morganella morganii 1 1
Proteus mirabilis 7 3 1 11
Pseudomonas aeruginosa 29 5 5 39
Pseudomonas stutzeri 1 1
Serratia liquefaciens 1 1
Serratia marcescens 7 2 9
Serratia plymuthica 1 1
Staphylococcus aureus 32 6 38
Staphylococcus epidermidis 10 10
Staphylococcus hominis 4 4
Stenotrophomonas maltophilia 12 12
Streptococcus grupo viridans 2 2
Streptococcus pneumoniae 14 14
Microbiological documentation of infectionwas obtained
in 137 patients (62.8%) (Table 1), with the identification of
262 different microorganisms from 185 respiratory samples,
26 urine samples, and 51 blood cultures (without considering
duplicates in the same sample type). Gram-negative bacteria
(63.7%) were the most frequent, followed by Gram-positive
bacteria (30.2%), fungi (5.0%), and anaerobes (1.1%). A single
microorganism was isolated in 68 (49.6%) of the patients (43
microorganisms in respiratory samples, 2 in urine samples,
and 23 in blood cultures), while multiple microorganisms
were isolated from the same or different samples in the
remaining 69 patients. Microorganisms were isolated from
respiratory samples alone in 74 patients, from blood cultures
alone in 24 patients, and from urine samples alone in 2
patients; in the remaining 37 patients, microorganisms were
isolated from two or more samples from different infection
foci. Nomicroorganismswere isolated in culture in 81 (37.2%)
of the patients, whose clinical suspicion of infection was not
microbiologically confirmed.
3.1. Assessment of Appropriateness of Antibiotic Prescriptions
that Follow LRM Guidelines. Empiric antibiotic treatment
was implemented for suspicion of nosocomial infection in 173
of the 218 study patients (79.4%), but LRM guidelines were
only followed in 44 of these (25.4%) (Table 2). When clinical
criteria lone were adopted, the most frequently prescribed
antibiotics were amoxicillin-clavulanic acid, vancomycin,
levofloxacin, carbapenems (meropenem or imipenem), and
ceftriaxone. When LRM guidelines were followed, the most
frequently antibiotics prescribed were carbapenems, van-
comycin, piperacillin-tazobactam, amikacin, and linezolid.
After sample culture, microorganisms were isolated in 77
of the 129 patients (59.7%) prescribed according to clinical
criteria and in 15 (34.1%) of the 44 patients prescribed in
accordance with LRM guidelines.
The empiric treatment was a single antibiotic in 76
(43.9%) of the 173 patients (amoxicillin-clavulanic acid in
43 [56.6%] of cases); two antibiotics in 47 (27.2%) of the
173 patients, three in 41 (23.7%), and four in 9 (5.2%).
Monotherapy was prescribed in 51.8% of patients treated
according to clinical criteria (amoxicillin-clavulanic acid in
64.2% of cases) versus 20.5% of those treated according to
LRM. The appropriateness of the empiric antibiotic treat-
ments was evaluated by analyzing the antibiotics prescribed
in the 92 patients for whom an antibiogram of the isolated
microorganism was available. In the 77 of these patients
treated according to clinical criteria, 36.4% of the antibiotics
prescribed to this group proved to be active against the
isolated bacteria, in comparison to 80.0% of the 15 patients
treated according to LRM guidelines. Hence, the percentage
appropriateness of the empiric antibiotic treatment was
significantly higher (𝑃 = 0.005) when LRM guidelines were
followed.
3.2. Assessment of Appropriateness of PMRTR Recommenda-
tions. The microbiology laboratory issued 139 PMRTRs for
96 (44.0%) of the 218 patients in the study, with a total of
362 recommendations for antibiotic therapy (Table 2). When
Gram-negative bacilli were isolated in culture, the most fre-
quently recommended antibiotics were imipenem, amikacin,
and piperacillin-tazobactam; when Gram-positive cocci in
clusters were isolated, they were linezolid and vancomycin,
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and when Gram-positive cocci in chains were isolated, they
were vancomycin and levofloxacin. The appropriateness of
PMRTR therapeutic recommendations was evaluated by
comparing each of the 362 recommended antibiotics with the
definitive antibiogram of the microorganism(s) eventually
identified in each patient, which showed that 90.3% of
recommended antibiotics were active against the identified
bacterium/bacteria.
3.3. Assessment of Appropriateness of Antibiotic Prescrip-
tion after Receipt of PMRTR Recommendations. Antibiotic
treatment prescription recommendations were followed in
68 (70.8%) of the 96 patients for whom a PMRTR was
issued, leading to the modification of initial empiric treat-
ment in 36 patients (52.9%), its maintenance in 4 patients
(5.9%), or the commencement of treatment in 28 previously
untreated patients (41.2%). Clinical criteria rather than the
received PMRTR were followed in 19 patients (19.8%). In the
remaining 9 patients (9.4%), PMRTRs were issued after ICU
discharge or death.
Table 2 shows that when the criteria were exclusively
clinical, the most frequently prescribed antibiotics were
ceftriaxone, tobramycin, carbapenems, and vancomycin, in
this order. However, when PMRTR recommendations were
followed, the most frequent were carbapenems, amikacin,
vancomycin, piperacillin-tazobactam, and linezolid. Com-
bined therapy with two antibiotics was predominant both in
the prescriptions following clinical criteria (mainly ceftriax-
one plus tobramycin) and in those following PMRTR (mainly
carbapenem plus amikacin).
The appropriateness of antibiotic prescriptions after
PMRTR receipt was assessed by comparing the antibiotic
prescribed to each patient with the definitive antibiogram
of the microorganism(s) finally identified in each sample.
According to the definitive antibiogram, 42.1% of the antibi-
otics prescribed following clinical criteria were active against
the isolated bacteria, whereas 82.4% of those prescribed in
accordance with PMRTR guidelines were active.The percent-
age appropriateness of antibiotic treatment prescription was
therefore significantly higher (𝑃 = 0.001) when PMRTR was
followed.
3.4. Global Assessment of GERB Use
3.4.1. GERB Use and Level of Associated Appropriateness.
As noted above, LRMs were followed for the prescription
of empiric antibiotic therapy in 44 (20.2%) of the 218
patients in the study and were not followed in 174 (79.8%)
patients. Active antibiotics against the isolated bacteria were
prescribed in 80.0% of the former group but in only 36.4%
of the latter. Out of the 87 patients with available PMRTR,
the recommendations were followed in 68 (78.2%) but not in
21 (21.8%) patients. Active antibiotics were prescribed against
isolated bacteria in 82.4% of the former cases but in only
42.1% of the latter.
LRM and PMRTR were both followed in only 8 (9.2%)
of the 87 patients for whom they were both available (LRM
for empiric treatment prescription, then PMRTR for modi-
fication of the initial treatment). Solely clinical criteria were
adopted in 32 (36.8%) of the patients, while either LRM or
PMRTR were followed in the remaining 47 (54.0%).
3.4.2. Mortality and Hospital Stay. The influence of GERB
(LRM and PMRTR) was evaluated on the two main clinical
variables: mortality and days of ICU stay. This analysis
only included the 137 patients with diagnostic certainty of
infection, that is, when a clinically significant microorganism
was isolated.
The mean ICU stay of patients who received empiric
treatment following LRM guidelines was 13.8 days, with a
mortality rate of 20.0%; their mean ICU admission APACHE
II score was 17.7. The mean ICU stay of patients who received
empiric treatment following clinical criteria was 19.5 days,
with a mortality rate of 27.3%; their mean ICU admis-
sion APACHE II score was 17.6. There were no significant
differences between patients receiving empiric treatment
according to LRM guidelines or clinical criteria in mortality
(𝑃 = 0.751) or days of stay (𝑃 = 0.156), even when
nonsurvivors were included in the analysis (𝑃 = 0.519).
The mean ICU stay of patients treated according to
PMRTR recommendations was 19.7 days, with a mortality
of 29.4%; their mean ICU admission APACHE II score was
18.0. The mean ICU stay of patients treated according to
clinical criteriawas 20.1, with amortality of 36.8%; theirmean
ICU admission APACHE II score was 19.0. There were no
significant differences between patients treated according to
PMRTR recommendations or clinical criteria in mortality
(𝑃 = 0.735) or days of stay (𝑃 = 0.943), even when
nonsurvivors were included (𝑃 = 0.219).
4. Discussion
Physicians should prescribe an appropriate empiric antibiotic
treatment in patients with clinical suspicion of infection.The
criteria adopted are usually based on their own experience
or on guidelines that are often developed in another setting,
even in another country. Hence, therapeutic treatment is
frequently not adapted to the microbial epidemiology of the
specific healthcare area, which may favor therapeutic failure.
Numerous publications by scientific societies and healthcare
institutions have emphasized the need to consider local
epidemiology in the development of therapeutic guidelines
for the prescription of empiric antibiotics [15–17, 21, 22].
Computerized decision support systems (CDSS) are clin-
ical consultation systems that assist physicians in diagnostic
and therapeutic decision making by analyzing patient and
population data. They have proven effective to improve med-
ical care, reduce prescription errors, and enhance compliance
with recommendations [28, 29]. These programs do not
replace clinical judgment but rather increase the information
available for physicians to be able to make correct decisions
[22]. A systematic review associated successful CDSS imple-
mentation with the integration of the system in the clinical
process and with the availability of recommendations at the
time and place of decision making [30].
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Evans et al. [28] evaluated the effects of a computerized
anti-infective-management program for real-time patient-
specific recommendations on the type of antimicrobial, dose,
administration route, and treatment duration, finding it to be
useful in surgical prophylaxis and in targeted and empiric
treatments; use of this program also significantly reduced
the number of days that patients received antimicrobial
treatment in the ICU. Thursky et al. [31] associated the
utilization of a real-time microbiology browser and CDSS
for antibiotic prescription with a reduction in total antibiotic
prescriptions, especially in themost widely prescribed broad-
spectrum antibiotics.
In the present study, GERB-derived LRMs permitted the
rates of bacterial resistance to antibiotics to be monitored,
based on the information in the LIS of the microbiology lab-
oratory. In general, this application permits (i) structuring of
epidemiologic data by hospital area and by infectious disease,
(ii) daily and automatic updating with new laboratory results,
(iii) presentation of the information in a web environment,
and (iv) presentation in readily interpreted graphics of data
on bacterial resistance to the antibiotics habitually used in the
treatment of a given infectious disease. After positive cultures
are obtained, PMRTRs provide a preliminary report on the
putative identification of isolated microorganism(s), issuing
therapeutic recommendations based on their most likely
susceptibility profile according to the local epidemiology
of the hospital unit and the specific infectious disease in
question.
According to the present results, the utilization of LRMs
and PMRTRs contributed to the adaptation of antibiotic
treatments, favoring the administration of the most active
antibiotics in clinical situation. The lower percentage appro-
priateness of empiric antibiotic treatments that followed
clinical criteria was related to the prescription of monother-
apy antibiotics, especially amoxicillin-clavulanic acid, or to
the use of combinations of narrow-spectrum antibiotics
with high microorganism resistance rates. The considerable
increase in percentage appropriateness with treatments fol-
lowing LRM and/or PMRTR guidelines was associated with
the prescription of antibiotics with very low resistance rates.
A major challenge in evaluating expert systems that
support therapeutic decisionmaking concerns the adherence
of physicians to their use, which was relatively low in the
present study, especially in relation to LRM guidelines.
Physicians may be reluctant to abandon their own criteria
or well-established antimicrobial therapy guidelines with
recognized prestige, especially in the prescription of empiric
treatments [32]. The much higher adherence to PMRTR may
be attributable to its provision of an explicit recommendation
in a printed report with the signature of a microbiology
specialist. Adherence to the GERB applications was stronger
when the clinical situation of the patient was more severe,
finding a mean APACHE II score of 21 in the eight patients
for whom LRM and PMRTR were followed, or when the
recommendation was to continue with the same antibiotic
therapy.
The results of this study did not support the hypothesis
that application of these GERB applications would signif-
icantly reduce the mortality rate and length of ICU stay.
Previous studies also found no significant reduction in
mortality after the development and implementation of local
treatment protocols, although these were associated with an
improvement in empiric therapy adaptation and a reduction
in the antibiotic treatment duration [13, 25].
In common with other investigations of measures
designed to improve antibiotic use, it was not possible
to conduct a randomized controlled trial, and the design
of our prospective study was therefore quasi-experimental.
Patients were not managed with a specific protocol, and it
was therefore not possible to control for all relevant clinical
variables. We cannot rule out the influence of unmeasured
variables and we did not evaluate the response to antibiotic
therapy according to predefined clinical variables. A further
limitation was the difficulty in assessing the clinical impact
of the GERB applications, because no microorganism was
isolated in a large percentage (37.2%) of patients; therefore,
although there was suspicion of infection, there was no
microbiological confirmation. It is likely that a large number
of the empiric treatments, following either clinical criteria or
LRM, were not for a true bacterial infection, although the
early onset of antibiotic treatment may possibly have avoided
growth of the microorganism in culture. The selection of one
antibiotic or another would not have determined the final
outcome in the first situation but may have done so in the
second. In fact, it is possible that the lower number of patients
in which a given microorganism was isolated when empiric
treatment was based on LRM guidelines (34.1%) is related
to the high appropriateness rates for antibiotic prescriptions
in line with these guidelines. Finally, our assessment of the
appropriateness of antibiotic treatments did not consider
the isolation of other microorganisms against which these
treatments are not active. This is the case of fungi, such as
Candida spp., which only represented 5% of the microorgan-
isms identified.
In conclusion, these new GERB applications offer
dynamic, highly accessible, and easily interpreted instru-
ments to assist physicians in the selection of antibiotic
treatment. Their implementation increases the percentage
of patients administered with an appropriate initial empiric
therapy. It would be of interest to perform a similar study in
different hospital departments over the same time period in
order to examine variations among them.
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